Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
HIV/AIDS
Research reports on HIV/AIDS from E.K. Quirk and colleagues provide new insights
January 14th, 2009
According to recent research from the United States, "We analyzed human immunodeficiency virus (HIV) seroresponses from 3 phase 1 HIV-1 vaccine trials to assess the frequency of vaccine-induced seroconversion. HIV-1 and HIV-2 enzyme-linked immunosorbent assay (ELISA) was performed during trials of adenovirus type 5 (Ad5)-vectored clade B HIV-1 monovalent gag and trivalent gag/pol/nef vaccines given to HIV-seronegative adults." "Doses were administered at day 1, week 4, and week 26. Results were analyzed by vaccine formulation and dose and were stratified by baseline Ad5 titer. ELISA-positive samples were reflexively tested by Western blotting. Overall, 165 (41%) of 406...
Source: Vaccine Weekly (2009-01-14)
|
